Dr. Reddy’s launches allergy drug
HYDERABAD, India — Dr. Reddy’s Labs has launched a drug used for treating allergies, the generic drug maker said Friday.
The Indian drug maker announced the launch of desloratadine orally disintegrating tablets in the 2.5-mg and 5-mg strengths. The drug is a generic version of Merck’s Clarinex Reditabs and is available in unit-dose packages of 30.
The branded version of the drug had sales of about $5.3 million during the 12-month period that ended in November 2012, according to IMS Health.
Ohio Northern University pharmacy students sponsor medication adherence events
ADA, Ohio — Students at an Ohio pharmacy school are taking part in a nationwide effort to boost medication adherence.
Ohio Northern University announced that the school’s chapter of the American Pharmacists Association — Academy of Student Pharmacists — had scheduled several events as part of the Medication Adherence Challenge, sponsored by the American Association of Colleges of Pharmacy.
The ONU APhA-ASP chapter will work with students and faculty from the university’s nursing program to consult and distribute information concerning medication adherence on Feb. 2 during the ONU Health Fair.
The group also will distribute information at the Ada, Ohio, Rite Aid store, as well as events at the Lima, Ohio, Rescue Mission and a local independent pharmacy.
The ONU chapter is focused on improving medication adherence at Allen County Health Partners in Lima through education, counseling, pill boxes, timers, refrigerator magnet reminders, calendar stickers, handouts, phone calls and text messages, the university said.
New indication approved for Genentech drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.
The FDA announced the approval of Avastin (bevacizumab) combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy for treating colorectal cancer that has spread to other parts of the body, also known as metastatic colorectal cancer, or mCRC.
The drug is also approved for treating lung cancer, kidney cancer and brain cancer.